Figure S7 from Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines

Dodson, Anne E.; Shenker, Sol; Sullivan, Pamela; Nayak, Sumeet U.; Middleton, Chris; McGuire, Michael; Chipumuro, Edmond; Mishina, Yuji; Tobin, Erica R.; Cadzow, Louise; Wylie, Andrew A.; Sangurdekar, Dipen

doi:10.1158/2767-9764.27979641

Figure S7 from Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines

journal contribution

posted on 2024-12-06, 09:20 authored by Anne E. Dodson, Sol Shenker, Pamela Sullivan, Sumeet U. Nayak, Chris Middleton, Michael McGuire, Edmond Chipumuro, Yuji Mishina, Erica R. Tobin, Louise Cadzow, Andrew A. Wylie, Dipen Sangurdekar

HRD predictions in relation to PARP inhibitor and platinum-based treatment response

History

ARTICLE ABSTRACT

HRD is common in cancer and can be exploited therapeutically, as it sensitizes cells to DNA-damaging agents. Here, we scored more than 1,300 cancer cell lines for HRD using two different bioinformatic approaches, thereby enabling large-scale analyses that provide insights into the etiology and features of HRD.